Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET
Company Participants
Vince Anzalone - Vice President, Investor Relations
Chris Anzalone - President & Chief Executive Officer
Javier San Martin - Chief Medical Officer
James Hamilton - Chief Discovery & Translational Medicine
Ken Myszkowski - Chief Financial Officer
Tracy Oliver - Chief Commercial Officer
Patrick O'Brien - Chief Operating Officer and General Counsel
Conference Call Participants
Edward Tenthoff - Piper Sandler
Ellie Merle - UBS
Maury Raycroft - Jefferies
Mani Foroohar - Leerink Partners
David Lebovitz - Citigroup
Luca Issi - RBC Capital Markets
Brendan Smith - TD Cowen
Mayank Mamtani - B. Riley Securities
Patrick Trucchio - H.C. Wainwright & Company
Prakhar Agrawal - Cantor Fitzgerald
Mike Ulz - Morgan Stanley
William Pickering - Bernstein
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone
Thank you, Justin. Good afternoon, and thank you for joining us today to discuss Arrowhead's results for its fiscal fourth quarter and year ended September 30, 2023. With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid and later-stage clinical pipeline; Dr. James Hamilton, our Chief of Discovery & Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, Tracy Oliver, our Chief Commercial Officer; and Patrick O'Brien, our Chief Operating Officer and General Counsel, will both be available during the Q&A portion of the call.
Before we begin, I would like to remind you that, comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our 10-K filed today and our quarterly reports on Form 10-Q.